Rapamycin in Frail Older Subjects with Heart Failure with Preserved Ejection Fraction
What this study shows
Trial of low-dose rapamycin in frail older adults with heart failure with preserved ejection fraction (HFpEF), from a Mayo Clinic/UW-Madison team including senolytics/mTOR-aging researchers Kirkland and Lamming; abstract not yet available (ahead-of-print).
Abstract
ShowHide
[Abstract not yet available in PubMed - ahead-of-print, indexed 2026-09-18]
Read the full abstract on PubMed →At a glance
ShowHide
| Evidence type | H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H. |
| Study type | 2 - Human Clinical Trial |
| Model system | Human (frail older adults with HFpEF) |
| Journal | Mayo Clinic Proceedings |
| Year | 2026 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1016/j.mayocp.2026.09.006 · PMID 42759606 |
Where this study fits
How this study connects to the pathway map, open questions, people and other studies in the Atlas.
People in the Atlas
-
Cardiologist at Mayo Clinic in Rochester, working in interventional cardiology, and first author of a trial of low-dose rapamycin in frail older adults with heart failure with preserved ejection fraction
-
Interventional cardiologist and professor of medicine at Mayo Clinic; corresponding author on a 2026 trial of low-dose rapamycin in frail older adults with heart failure with preserved ejection fraction (HFpEF)
-
Founder of the field of senolytics, drugs that clear senescent cells, and a leader of clinical trials of ageing-targeted therapies
-
Showed as a postdoc that rapamycin's harm to glucose metabolism comes largely from its effect on mTORC2, while the lifespan benefit tracks mTORC1. His Wisconsin lab studies intermittent rapamycin dosing and how restricting dietary protein or single amino acids affects metabolism and ageing
More: 11 other authors
No profile yet: Mill J, Ellingson P, James I, Borlaug BA, Olson TP, Bagwell MS, Lewis BR, Ingraham BS, Huxley S, Behfar A, Simcox JA
Related studies
- A
- H
- A
- M Recurrent reversible mutations at gaf1 driving metastable TORC1 inhibitor resistance in fission yeast.
DAN2026 · 2026 · Shares: Rapamycin
- H
More related studies
- H Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: pilot findings from phase-II observational study
GIL2026 · 2026 · Shares: Rapamycin
- M
- H
- M
- A Diet-dependent, beneficial and adverse effects of rapamycin on life span of Drosophila melanogaster
JAC2026 · 2026 · Shares: Rapamycin
- M Rapamycin co-exposure fails to reduce cisplatin-induced damage in GC6-spg spermatogonial cell line.
JIB2026 · 2026 · Shares: Rapamycin
- A
- A
Topics
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Low-dose rapamycin (details not available) |
| Target | mTOR |
| Model | Human (frail older adults with HFpEF) |
Thank you. Your answer was counted anonymously.